Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Thyroid Neoplasms 4Thyroid Cancer, Papillary 3Adenocarcinoma, Follicular 3Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

3-Iodobenzylguanidine 3cabozantinib 2pembrolizumab 1pazopanib 1lutetium Lu 177 dotatate 1guadecitabine 1gallium Ga 68 dotatate 1copper dotatate CU-64 1atezolizumab 1Sunitinib 1Radiosurgery 1Phenoxybenzamine 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Iodine-131 1Everolimus 1Erlotinib Hydrochloride 1Doxazosin 1Axitinib 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Paraganglioma × Iodine-131 × Clear all
NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡